BIOTE CORP -A (BTMD) Fundamental Analysis & Valuation

NASDAQ:BTMD • US0906831039

1.54 USD
-0.18 (-10.47%)
At close: Mar 12, 2026
1.54 USD
0 (0%)
After Hours: 3/12/2026, 5:30:22 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BTMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to BTMD. BTMD was compared to 193 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of BTMD get a neutral evaluation. Nothing too spectacular is happening here. BTMD is cheap, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

5

1. BTMD Profitability Analysis

1.1 Basic Checks

  • BTMD had positive earnings in the past year.
  • In the past year BTMD had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: BTMD reported negative net income in multiple years.
  • In multiple years BTMD reported negative operating cash flow during the last 5 years.
BTMD Yearly Net Income VS EBIT VS OCF VS FCFBTMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 25.87%, BTMD belongs to the top of the industry, outperforming 98.45% of the companies in the same industry.
  • The Return On Invested Capital of BTMD (45.22%) is better than 99.48% of its industry peers.
Industry RankSector Rank
ROA 25.87%
ROE N/A
ROIC 45.22%
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BTMD Yearly ROA, ROE, ROICBTMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 400 600

1.3 Margins

  • BTMD has a Profit Margin of 14.72%. This is amongst the best in the industry. BTMD outperforms 87.56% of its industry peers.
  • In the last couple of years the Profit Margin of BTMD has declined.
  • BTMD has a better Operating Margin (16.09%) than 86.53% of its industry peers.
  • BTMD's Operating Margin has declined in the last couple of years.
  • With a decent Gross Margin value of 72.23%, BTMD is doing good in the industry, outperforming 78.76% of the companies in the same industry.
  • In the last couple of years the Gross Margin of BTMD has grown nicely.
Industry RankSector Rank
OM 16.09%
PM (TTM) 14.72%
GM 72.23%
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
BTMD Yearly Profit, Operating, Gross MarginsBTMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. BTMD Health Analysis

2.1 Basic Checks

  • BTMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • BTMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BTMD Yearly Shares OutstandingBTMD Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
BTMD Yearly Total Debt VS Total AssetsBTMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 2.15 indicates that BTMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 2.15, BTMD is in the better half of the industry, outperforming 63.21% of the companies in the same industry.
  • The Debt to FCF ratio of BTMD is 4.18, which is a neutral value as it means it would take BTMD, 4.18 years of fcf income to pay off all of its debts.
  • BTMD has a Debt to FCF ratio of 4.18. This is amongst the best in the industry. BTMD outperforms 84.97% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.18
Altman-Z 2.15
ROIC/WACC5.21
WACC8.68%
BTMD Yearly LT Debt VS Equity VS FCFBTMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

  • A Current Ratio of 1.01 indicates that BTMD should not have too much problems paying its short term obligations.
  • BTMD has a worse Current ratio (1.01) than 82.38% of its industry peers.
  • A Quick Ratio of 0.72 indicates that BTMD may have some problems paying its short term obligations.
  • BTMD has a Quick ratio of 0.72. This is amonst the worse of the industry: BTMD underperforms 83.42% of its industry peers.
Industry RankSector Rank
Current Ratio 1.01
Quick Ratio 0.72
BTMD Yearly Current Assets VS Current LiabilitesBTMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. BTMD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 277.27% over the past year.
EPS 1Y (TTM)277.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-6.87%

3.2 Future

  • The Earnings Per Share is expected to grow by 9.65% on average over the next years. This is quite good.
  • BTMD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.86% yearly.
EPS Next Y-69.28%
EPS Next 2Y-41.34%
EPS Next 3Y11.89%
EPS Next 5Y9.65%
Revenue Next Year2.37%
Revenue Next 2Y5.39%
Revenue Next 3Y10.42%
Revenue Next 5Y8.86%

3.3 Evolution

BTMD Yearly Revenue VS EstimatesBTMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
BTMD Yearly EPS VS EstimatesBTMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

7

4. BTMD Valuation Analysis

4.1 Price/Earnings Ratio

  • BTMD is valuated cheaply with a Price/Earnings ratio of 1.86.
  • BTMD's Price/Earnings ratio is rather cheap when compared to the industry. BTMD is cheaper than 98.45% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of BTMD to the average of the S&P500 Index (26.15), we can say BTMD is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 6.04, the valuation of BTMD can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, BTMD is valued cheaply inside the industry as 93.26% of the companies are valued more expensively.
  • BTMD's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.27.
Industry RankSector Rank
PE 1.86
Fwd PE 6.04
BTMD Price Earnings VS Forward Price EarningsBTMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BTMD is valued cheaper than 96.37% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, BTMD is valued cheaper than 98.96% of the companies in the same industry.
Industry RankSector Rank
P/FCF 2.04
EV/EBITDA 5.5
BTMD Per share dataBTMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.34%
EPS Next 3Y11.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BTMD Dividend Analysis

5.1 Amount

  • BTMD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BTMD Fundamentals: All Metrics, Ratios and Statistics

BIOTE CORP -A

NASDAQ:BTMD (3/12/2026, 5:30:22 PM)

After market: 1.54 0 (0%)

1.54

-0.18 (-10.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-11
Earnings (Next)N/A
Inst Owners63.61%
Inst Owner Change0.4%
Ins Owners10.06%
Ins Owner Change0%
Market Cap70.32M
Revenue(TTM)N/A
Net Income(TTM)28.79M
Analysts81.82
Price Target4.94 (220.78%)
Short Float %5.72%
Short Ratio10.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)270.4%
Min EPS beat(2)178.65%
Max EPS beat(2)362.15%
EPS beat(4)3
Avg EPS beat(4)249.23%
Min EPS beat(4)-1.96%
Max EPS beat(4)458.07%
EPS beat(8)5
Avg EPS beat(8)105.05%
EPS beat(12)7
Avg EPS beat(12)16.44%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.43%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)-1.55%
Revenue beat(4)1
Avg Revenue beat(4)-1.97%
Min Revenue beat(4)-4.66%
Max Revenue beat(4)1.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.65%
Revenue beat(12)4
Avg Revenue beat(12)-1.32%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.91%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 1.86
Fwd PE 6.04
P/S 0.36
P/FCF 2.04
P/OCF 1.76
P/B N/A
P/tB N/A
EV/EBITDA 5.5
EPS(TTM)0.83
EY53.9%
EPS(NY)0.26
Fwd EY16.56%
FCF(TTM)0.75
FCFY48.94%
OCF(TTM)0.88
OCFY56.88%
SpS4.28
BVpS-1.59
TBVpS-1.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 25.87%
ROE N/A
ROCE 57.24%
ROIC 45.22%
ROICexc 92.24%
ROICexgc 190.38%
OM 16.09%
PM (TTM) 14.72%
GM 72.23%
FCFM 17.59%
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-32.05%
ROICexgc growth 5YN/A
ROICexc growth 3Y-33.38%
ROICexc growth 5YN/A
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
F-Score7
Asset Turnover1.76
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.18
Debt/EBITDA 3.02
Cap/Depr 144.67%
Cap/Sales 2.85%
Interest Coverage 3.81
Cash Conversion 113.15%
Profit Quality 119.51%
Current Ratio 1.01
Quick Ratio 0.72
Altman-Z 2.15
F-Score7
WACC8.68%
ROIC/WACC5.21
Cap/Depr(3y)122.96%
Cap/Depr(5y)152.59%
Cap/Sales(3y)2.04%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)277.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40%
EPS Next Y-69.28%
EPS Next 2Y-41.34%
EPS Next 3Y11.89%
EPS Next 5Y9.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-6.87%
Revenue Next Year2.37%
Revenue Next 2Y5.39%
Revenue Next 3Y10.42%
Revenue Next 5Y8.86%
EBIT growth 1Y-29.68%
EBIT growth 3Y-2.97%
EBIT growth 5Y6.11%
EBIT Next Year30.98%
EBIT Next 3Y13.56%
EBIT Next 5Y13.39%
FCF growth 1Y43.63%
FCF growth 3Y8.58%
FCF growth 5Y10.09%
OCF growth 1Y53.94%
OCF growth 3Y10.29%
OCF growth 5Y12.28%

BIOTE CORP -A / BTMD FAQ

Can you provide the ChartMill fundamental rating for BIOTE CORP -A?

ChartMill assigns a fundamental rating of 4 / 10 to BTMD.


Can you provide the valuation status for BIOTE CORP -A?

ChartMill assigns a valuation rating of 7 / 10 to BIOTE CORP -A (BTMD). This can be considered as Undervalued.


Can you provide the profitability details for BIOTE CORP -A?

BIOTE CORP -A (BTMD) has a profitability rating of 5 / 10.


How financially healthy is BIOTE CORP -A?

The financial health rating of BIOTE CORP -A (BTMD) is 4 / 10.


How sustainable is the dividend of BIOTE CORP -A (BTMD) stock?

The dividend rating of BIOTE CORP -A (BTMD) is 0 / 10 and the dividend payout ratio is 0%.